Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 20,890 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Non-treatment Clear all
Not listed Not applicable Interventional

Neonatal Brain Oxygenation Study

NCT04439968
View directory record Official record
Conditions
Cerebral Hypoxia
Interventions
Clinical algorithm
Other
Lead sponsor
Stanford University
Other
Eligibility
Up to 2 Days
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 24, 2026, 5:32 AM EDT
Recruiting Not applicable Interventional

MRE Scan for the Assessment of Differences in Tissue Stiffness Between Radiation Necrosis and Recurrent Glioma in Patients With Previously Treated Gliomas

NCT04373720
View directory record Official record
Conditions
Glioma
Interventions
Magnetic Resonance Elastography, Magnetic Resonance Imaging
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 24, 2026, 5:32 AM EDT
Recruiting No phase listed Observational

Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT

NCT05938478
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Tralokinumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Female only
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2035
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 24, 2026, 5:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

NCT03037385
View directory record Official record
Conditions
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, RET-altered Colon Cancer, RET-altered Solid Tumors, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Thyroid Diseases, Thyroid Neoplasm, Thyroid Cancer, Papillary, Carcinoma, Neuroendocrine, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Disease, Carcinoma, Bronchogenic, Bronchial Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasm, Head and Neck Neoplasms, Adenocarcinoma, Papillary, Adenocarcinoma, Carcinoma, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Neuroendocrine Tumors, Neuroectodermal Tumors, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Colonic Neoplasms, Colorectal Neoplasms, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasm, Digestive System Disease, Gastrointestinal Disease, Colonic Diseases, Intestinal Disease
Interventions
pralsetinib (BLU-667)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
18
States / cities
Phoenix, Arizona • Orange, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 24, 2026, 5:32 AM EDT
Completed Not applicable Interventional Results available

Electrical Stimulation for the Treatment of Chronic Post-Stroke Shoulder Pain Using the Smartpatch System

NCT01847885
View directory record Official record
Conditions
Post-stroke Shoulder Pain, Hemiplegic Shoulder Pain
Interventions
Smartpatch Peripheral Nerve Stimulation (PNS) System
Device
Lead sponsor
SPR Therapeutics, Inc.
Industry
Eligibility
21 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Chicago, Illinois • West Orange, New Jersey • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 24, 2026, 5:32 AM EDT
Completed No phase listed Observational

Expression & Epigenetic Silencing of MicroRNA for Predicting Therapeutic Response and Prognosis of HPV-negative HNSCC

NCT03953443
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Not interventional
Other
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 24, 2026, 5:32 AM EDT
Terminated Phase 4 Interventional Results available

Effects of Abatacept on Myocarditis in Rheumatoid Arthritis

NCT03619876
View directory record Official record
Conditions
Rheumatoid Arthritis, Myocardial Inflammation
Interventions
Abatacept, Adalimumab
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Oct 24, 2026, 5:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Brain Activation and Satiety in Children: Functional Magnetic Resonance Imaging

NCT02484976
View directory record Official record
Conditions
Childhood Obesity
Interventions
Family Based Behavioral Treatment
Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
9 Years to 11 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 24, 2026, 5:32 AM EDT
Recruiting Phase 2 Interventional

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

NCT06364917
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed, Nivolumab, Ipilimumab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 24, 2026, 5:32 AM EDT
Completed Phase 4 Interventional Results available

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

NCT02869789
View directory record Official record
Conditions
Lung Cancer
Interventions
Nivolumab in combination with Ipilimumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,041 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 24, 2026, 5:32 AM EDT
Completed Not applicable Interventional

Cognitive Behavioral Therapy in Treating Anxiety in Patients With Stage IV Non-Small Cell Lung Cancer and Their Caregivers

NCT01729689
View directory record Official record
Conditions
Anxiety Disorder, Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
counseling intervention, questionnaire administration, quality-of-life assessment
Other · Procedure
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Oct 24, 2026, 5:32 AM EDT
Completed Not applicable Interventional

Cell Phone Reminders Intervention

NCT01049568
View directory record Official record
Conditions
HAART Non-Adherence, HIV, HIV Infections
Interventions
Cell Phone Intervention
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years to 24 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 24, 2026, 5:32 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma

NCT00003150
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, CHOP regimen, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
60 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
91
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 24, 2026, 5:32 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Sensorimotor Dysfunction in Achalasia

NCT02434991
View directory record Official record
Conditions
Achalasia
Interventions
Barostat
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 24, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single-Dose Study to Evaluate the PKs of Pretomanid in Participants With Renal Impairment Compared to Participants With Normal Renal Function

NCT03896750
View directory record Official record
Conditions
Renal Impairment, Tuberculosis
Interventions
PA-824
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Miami, Florida • St Louis, Missouri • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 24, 2026, 5:32 AM EDT
Terminated Not applicable Interventional Results available

Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement

NCT02673697
View directory record Official record
Conditions
Aortic Valve Disease, Aortic Stenosis
Interventions
Perceval valve, other stented biological valve
Device
Lead sponsor
Corcym S.r.l
Industry
Eligibility
18 Years and older
Enrollment
914 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
5
States / cities
Indianapolis, Indiana • Portland, Maine • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 24, 2026, 5:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

NCT02858310
View directory record Official record
Conditions
Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, Vulvar Diseases
Interventions
E7 TCR cells, Aldesleukin, Fludarabine, Cyclophosphamide, EKG, Biopsy, Chest CT and MRI or PET, PFT, Granisetron, Ondansetron, Droperidol, Prochlorperazine, Diphenoxylate HCL, Atropine sulfate, Codeine sulfate, Loperamide, Indomethacin, Acetaminophen, Diphenhydramine HCL, Hydroxyzine HCL, Meperidine
Biological · Drug · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Bethesda, Maryland • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 24, 2026, 5:32 AM EDT
Completed Not applicable Interventional

Comparison of Humidified High Flow Nasal Cannula to Nasal CPAP in Neonates

NCT00609882
View directory record Official record
Conditions
Respiratory Insufficiency
Interventions
Nasal CPAP, Humidified High Flow Nasal Cannula (HHFNC)
Other
Lead sponsor
University of Utah
Other
Eligibility
Up to 8 Weeks
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
8
States / cities
Philadelphia, Pennsylvania • Lackland Air Force Base, Texas • Ogden, Utah + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 24, 2026, 5:32 AM EDT
Terminated Phase 1 Interventional Results available

Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

NCT04809623
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus
Interventions
Edecesertib, Placebo, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Beverly Hills, California • Clearwater, Florida • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 24, 2026, 5:32 AM EDT
Completed Phase 1 Interventional

Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer

NCT01839955
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
erlotinib hydrochloride, quinacrine dihydrochloride - Escalation dose, laboratory biomarker analysis, pharmacological study, quinacrine dihydrochloride - Extension dose
Drug · Other
Lead sponsor
Neelesh Sharma MD PhD
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Oct 24, 2026, 5:32 AM EDT
Recruiting Phase 3 Interventional

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

NCT07190248
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Calderasib, Pembrolizumab (+) Berahyaluronidase alfa, Pemetrexed, Cisplatin, Carboplatin
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
15
States / cities
Birmingham, Alabama • Farmington, Connecticut • Stamford, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 24, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC

NCT02591615
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
MK-3475, Carboplatin, Paclitaxel, Pemetrexed
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
La Jolla, California • Chicago, Illinois • Evanston, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Oct 24, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

NCT01010217
View directory record Official record
Conditions
Blood Stem Cell Transplant Failure, Leukemia, Hematologic Malignancies
Interventions
Cyclophosphamide, Fludarabine, Melphalan, Mesna, Rituximab, Stem Cell Transplantation, Thiotepa, Tacrolimus, Mycofenolate mofetil, G-CSF
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 75 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 24, 2026, 5:32 AM EDT
Completed Not applicable Interventional

A Carbohydrate-restricted Diet to Reverse Fatty Liver in Adolescents With Obesity

NCT02787668
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Childhood Obesity, Insulin Resistance
Interventions
Carbohydrate-restricted diet, Control, low-fat diet
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
9 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Oct 24, 2026, 5:32 AM EDT